Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating MYOM3 fragments reflect disease severity and therapeutic efficacy in tubular aggregate myopathy and Stormorken syndrome.

Human molecular genetics·2026
Same author

DNM2 lipid binding drives centronuclear myopathy and represents a potential therapeutic target.

JCI insight·2026
Same author

Changing Prevalence of Immunocompromising Conditions in Patients Hospitalized with Severe Acute Respiratory Infection in Europe: Insights from the COVIDRIVE Study.

Journal of epidemiology and global health·2026
Same author

Muscle-Specific DNM2 Overexpression Improves Charcot-Marie-Tooth Disease In Vivo and Reveals a Narrow Therapeutic Window in Skeletal Muscle.

International journal of molecular sciences·2026
Same author

Myomerger-derived peptide enhances skeletal muscle tropism and reduces liver transduction of lipid nanoparticles for gene delivery.

Molecular therapy. Nucleic acids·2025
Same author

Tamoxifen treatment fails to improve muscle dysfunction in a model of recessive RYR1-linked centronuclear myopathy.

Disease models & mechanisms·2025

Related Experiment Video

Updated: May 2, 2026

Improved Protocol for Chromatin Immunoprecipitation from Mouse Skeletal Muscle
09:30

Improved Protocol for Chromatin Immunoprecipitation from Mouse Skeletal Muscle

Published on: November 6, 2017

8.1K

Reducing dynamin 2 expression rescues X-linked centronuclear myopathy.

Belinda S Cowling, Thierry Chevremont, Ivana Prokic

    The Journal of Clinical Investigation
    |February 27, 2014
    PubMed
    Summary
    This summary is machine-generated.

    Reducing dynamin 2 (DNM2) levels significantly improved lifespan and muscle function in a mouse model of X-linked myotubular myopathy (XLCNM). This suggests DNM2 is a potential therapeutic target for this severe muscle disorder.

    More Related Videos

    A Non-random Mouse Model for Pharmacological Reactivation of Mecp2 on the Inactive X Chromosome
    08:27

    A Non-random Mouse Model for Pharmacological Reactivation of Mecp2 on the Inactive X Chromosome

    Published on: May 22, 2019

    6.0K
    Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
    10:30

    Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

    Published on: May 24, 2016

    19.7K

    Related Experiment Videos

    Last Updated: May 2, 2026

    Improved Protocol for Chromatin Immunoprecipitation from Mouse Skeletal Muscle
    09:30

    Improved Protocol for Chromatin Immunoprecipitation from Mouse Skeletal Muscle

    Published on: November 6, 2017

    8.1K
    A Non-random Mouse Model for Pharmacological Reactivation of Mecp2 on the Inactive X Chromosome
    08:27

    A Non-random Mouse Model for Pharmacological Reactivation of Mecp2 on the Inactive X Chromosome

    Published on: May 22, 2019

    6.0K
    Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
    10:30

    Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

    Published on: May 24, 2016

    19.7K

    Area of Science:

    • Muscle biology
    • Genetics
    • Neuromuscular disorders

    Background:

    • X-linked myotubular myopathy (XLCNM) is a severe congenital disorder causing muscle weakness and early death.
    • Current treatments for XLCNM are ineffective.
    • Increased dynamin 2 (DNM2) levels are observed in XLCNM patients and models.

    Purpose of the Study:

    • To investigate the role of DNM2 in XLCNM.
    • To determine if reducing DNM2 can ameliorate XLCNM symptoms.

    Main Methods:

    • Generated XLCNM mice (Mtm1(-/y)) with reduced DNM2 levels.
    • Assessed lifespan, muscle strength, diaphragm function, and histology.
    • Performed skeletal muscle-specific Dnm2 decrease during development and after disease onset.

    Main Results:

    • Reduction of DNM2 in XLCNM mice restored lifespan, whole-body and muscle strength, and diaphragm function.
    • Histological features of CNM, including fiber atrophy and nuclei mispositioning, were reduced.
    • Decreasing Dnm2 levels halted and potentially reversed XLCNM progression in a cell-autonomous manner.

    Conclusions:

    • MTM1 and DNM2 regulate muscle organization and force via a common pathway.
    • Reducing DNM2 is a promising therapeutic strategy for XLCNM.